Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q4 FY20 results · Jan–Mar 2020
Aarti Drugs reported revenue from operations of ₹449.64 crore (down 2.1% from Q4 FY19) and net profit of ₹58.86 crore (up 114.5% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 449.64 | 459.14 | −2.1% | 473.51 | −5.0% |
| Other income | 0.99 | 4.99 | −80.2% | 0.25 | +296.0% |
| Total income | 450.63 | 464.13 | −2.9% | 473.76 | −4.9% |
| Profit before tax | 60.72 | 39.75 | +52.8% | 43.08 | +40.9% |
| Net profit for the period | 58.86 | 27.44 | +114.5% | 27.78 | +111.9% |
| EPS, basic (₹) | 25.26 | 12.06 | +109.5% | 11.92 | +111.9% |
| Net margin (%) | 13.1 | 6.0 | 5.9 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 406.57 | 432.54 | −6.0% | 415.61 | −2.2% |
| Other income | 0.62 | 5.03 | −87.7% | 0.13 | +376.9% |
| Total income | 407.19 | 437.57 | −6.9% | 415.74 | −2.1% |
| Profit before tax | 57.36 | 37.51 | +52.9% | 39.50 | +45.2% |
| Net profit for the period | 56.56 | 25.69 | +120.2% | 26.75 | +111.4% |
| EPS, basic (₹) | 24.28 | 11.31 | +114.7% | 11.48 | +111.5% |
| Net margin (%) | 13.9 | 5.9 | 6.4 |
Consolidated
- Filed with BSE
- 18 May 2020, 10:21 IST
- Board meeting
- 15 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 May 2020, 10:21 IST
- Board meeting
- 15 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE